FY2017 · ended Dec 31, 2017 · Revenue $295,000, -54.8% YoY · Filed Apr 1, 2019
Tempest Therapeutics, Inc. (TPST) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$26.8 million. As of Jun 30, 2026 it held $779,000 in cash and investments and $7.6 million in total debt.
Revenue (TTM)
$294,000
-9.5% vs year-ago TTM
Net income (TTM)
$-58.77M
+9.7% vs year-ago TTM
Operating cash flow (TTM)
$-20.73M
+43.7% vs year-ago TTM
Free cash flow (TTM)
$-20.73M
+43.7% vs year-ago TTM
EPS
$-6.33
+67.5% vs prior year
Dividend per share
$0.00
Shares outstanding
14.34M
+292.4% vs prior year
Net cash
$-6.78M
as of Jun 30, 2026
Operating margin
-20266.7%
FY 2018
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TPST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1544227
- Former names
- Millendo Therapeutics, Inc. (until Jul 1, 2021); OvaScience, Inc. (until Dec 6, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$26.6M | -$42.0M | -$29.2M | -$34.6M | -$27.0M |
| Net income | -$26.3M | -$41.8M | -$29.5M | -$35.7M | -$28.3M |
| Diluted EPS | -$6.33 | -$19.50 | -$1.91 | -$3.09 | -$7.47 |
| Operating cash flow | -$26.8M | -$33.0M | -$27.4M | -$31.1M | -$26.0M |
| Free cash flow | -$26.8M | -$33.5M | -$27.5M | -$31.6M | -$26.1M |
| Total assets | $16.9M | $41.5M | $51.6M | $46.1M | $73.2M |
| Total liabilities | $10.3M | $22.4M | $24.8M | $28.0M | $37.1M |
| Stockholders' equity | $6.7M | $19.1M | $26.8M | $18.1M | $36.1M |
| Cash and investments | $7.7M | $30.3M | $39.2M | $31.2M | $51.8M |
| Total debt | $8.1M | $15.4M | $20.7M | $22.1M | $18.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Nov 2, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 30, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Oct 20, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 19, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Regulation FD disclosure
|
Sep 28, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 17, 2026 | Sep 14, 2026 |
All 1000 Tempest Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.